ITM-11 Shows Superior GEP-NET Response in Phase 3 Trial
Progression-free survival reached 23.9 months with 177Lu-edotreotide versus 14.1 months on everolimus in the Phase 3 COMPETE trial (HR...
Rani Therapeutics’ Surging $60.3M Private Placement Closes
Rani Therapeutics closed a $60.3 million gross private placement structured as common stock and pre-funded warrants priced at approximately...
Acrivon Highlights AP3 Platform, ACR-2316 Preclinical Data
Acrivon reported early clinical activity for its dual WEE1/PKMYT1 inhibitor ACR-2316, including a confirmed partial response during Phase 1...
Telix Doses First Patient in SOLACE Trial for Bone Pain
No efficacy data yet. Telix has initiated dosing in SOLACE, an open-label Phase 1 trial (NCT07197645) enrolling up to...
Elironrasib Safety, Efficacy Data in KRAS G12C Lung Cancer
Elironrasib delivered a confirmed objective response rate of 42% (95% CI: 22–63) and a disease control rate of 79%...
Frontier Medicines Presents Preclinical Data on 3 Programs
Frontier Medicines reported preclinical signals across three oncology programs: FMC-376 suppressed tumor growth in KRAS G12C-mutant patient-derived xenograft models,...
Femasys Begins New FemBloc® Birth Control Study in Europe
Femasys has initiated a post‑market surveillance clinical study for its CE‑marked FemBloc permanent birth control device in Europe, structured...
Alector Reveals Topline Data for Phase 3 FTD Drug Trial
In the 96-week Phase 3 INFRONT-3 study in FTD due to GRN mutations, latozinemab failed to slow clinical progression...
Fortress Doses First Patients in Pivotal Gout Drug Trial
Crystalys Therapeutics has dosed the first patients in two global, randomized, double-blind Phase 3 trials of dotinurad, a once-daily...
New Clinical Sites Added for BriaCell’s Phase 3 Cancer Trial
Seventy-nine U.S. sites across 23 states are now open in BriaCell’s pivotal Phase 3 program in metastatic breast cancer,...